Compare MTEK & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTEK | GDTC |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Israel | Singapore |
| Employees | 14 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 12.4M |
| IPO Year | N/A | 2021 |
| Metric | MTEK | GDTC |
|---|---|---|
| Price | $1.16 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 351.5K | 19.0K |
| Earning Date | 05-12-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.68 |
| 52 Week High | $4.27 | $3.68 |
| Indicator | MTEK | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 52.01 |
| Support Level | $1.08 | $0.93 |
| Resistance Level | $1.44 | $1.25 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 38.46 | 3.46 |
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.